<DOC>
	<DOCNO>NCT00331747</DOCNO>
	<brief_summary>Hypothesis : Treatment Glatiramer acetate prevents deterioration gait multiple sclerosis ( MS ) patient . During study patient undergo 3 dimensional gait analysis start treatment glatiramer acetate 1 year treatment .</brief_summary>
	<brief_title>Gait Evaluation Multiple Sclerosis Patients Treated With Glatiramer Acetate</brief_title>
	<detailed_description>Patients definite diagnosis relapse remit multiple sclerosis ( MS ) undergo 3 dimensional gait analysis initiation treatment glatiramer acetate . The gait analysis include kinematic evaluation use Charnwood Dynamics CODA CX-1 system , 4 AMTI force plate Noraxon telemetric EMG system . Patients videotape also undergo detailed physical examination physical therapist . Treatment Glatiramer acetate initiate gait analysis . Therapy observe controlled neurologist fromn staff Multiple Sclerosis Center . Repeat gait analysis perform one year treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Clinical diagnosis multiple sclerosis EDSS le 5.5 No cognitive disability EDSS 5.5 Inability cooperate gait analysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>